Abstract
The purpose is to determine the effect of food on the bioavailability of S-1, an oral formulation of the 5-fluorouracil (5FU) prodrug Ftorafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), a dihydropyrimidine dehydrogenase inhibitor, and oxonic acid (an inhibitor of 5FU phosphoribosylation in normal gut mucosa) in a molar ratio of 1:0.4:1. Eighteen patients received a single dose of S-1 of 35 mg/m(2) with (535-885 kcal) or without food in a crossover study design: in arm A without breakfast on day -7 and with breakfast on day 0 and in arm B the reversed sequence. Blood samples were taken before and after S-1 administration. This food effect was evaluated according to the Food and Drug Administration guidelines using log-transformed data. Pharmacokinetic parameters for 5FU without breakfast were as follows: Tmax, 107 min; Cmax, 1.60 microm; area under the plasma concentration-time curve (AUC) 441 microm x min; and T(1/2), 104 min. Fasting decreased Tmax of FT, 5FU, CDHP, and oxonic acid significantly (P < 0.006) and increased the Cmax (P < 0.013). The food/fast ratio for the AUC of FT was not different, which for 5FU was 0.84 (P = 0.041), for CDHP was 0.89 (P = 0.191), for oxonic acid was 0.48 (P < 0.0005), and for cyanuric acid,...Continue Reading
References
Apr 1, 1989·Clinical Pharmacokinetics·R B Diasio, B E Harris
Aug 1, 1980·Clinical Pharmacology and Therapeutics·J M CollinsC E Myers
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R L SchilskyH A Burris
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Mar 16, 2000·Journal of Chromatography. B, Biomedical Sciences and Applications·D BiC H Takimoto
Jul 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C J van GroeningenG Giaccone
Jul 20, 2000·British Journal of Cancer·A OhtsuT Taguchi
Jul 27, 2000·Cancer Chemotherapy and Pharmacology·K YoshisueY Kawaguchi
Nov 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J PetersG Giaccone
Jan 31, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M M BornerP Fumoleau
Apr 27, 2002·Cancer Chemotherapy and Pharmacology·Dale R ShepardMark J Ratain
Jul 12, 2002·Cancer Chemotherapy and Pharmacology·Masataka IkedaTakashi Satomi
Nov 28, 2002·Clinical Colorectal Cancer·Robert B Diasio
Mar 28, 2003·British Journal of Cancer·J Van den BrandeP Fumoleau
Citations
Jun 21, 2006·Cancer Chemotherapy and Pharmacology·Andrew X ZhuMatthew H Kulke
Oct 25, 2011·Cancer Chemotherapy and Pharmacology·Max E ScheulenDirk Strumberg
Jun 17, 2011·Future Oncology·Mariela BlumJaffer A Ajani
Jan 13, 2012·Expert Opinion on Drug Delivery·Koh MiuraIwao Sasaki
Jan 27, 2016·Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology·Eriseld KrasniqiVincenzo Formica
Dec 15, 2010·Cancer Science·Benjamin ChuahLee S Rosen
Sep 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaffer A AjaniPeter Urrea
Apr 6, 2017·Expert Opinion on Drug Delivery·Koh MiuraRyuichi Katakura
Oct 5, 2011·Oncology·Ki Y ChungLeonard B Saltz
Oct 14, 2009·Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry·Yuan GuChangxiao Liu